O Shaughnessy Asset Management LLC Decreases Position in ResMed Inc. $RMD

Posted by Stanley Muller on Jun 11th, 2026

O Shaughnessy Asset Management LLC lessened its position in shares of ResMed Inc. (NYSE:RMD – Free Report) by 12.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 29,949 shares of the medical equipment provider’s stock after selling 4,289 shares during the period. O Shaughnessy Asset Management LLC’s holdings in ResMed were worth $7,214,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in RMD. International Assets Investment Management LLC purchased a new position in shares of ResMed during the 4th quarter valued at $25,000. ORG Partners LLC lifted its position in shares of ResMed by 181.6% during the 4th quarter. ORG Partners LLC now owns 107 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 69 shares during the last quarter. Imprint Wealth LLC purchased a new position in shares of ResMed during the 3rd quarter valued at $26,000. WFA of San Diego LLC purchased a new position in shares of ResMed during the 2nd quarter valued at $26,000. Finally, Sunbelt Securities Inc. purchased a new position in shares of ResMed during the 3rd quarter valued at $31,000. Hedge funds and other institutional investors own 54.98% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on RMD. Wall Street Zen cut ResMed from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. Citigroup dropped their price target on ResMed from $345.00 to $340.00 and set a “buy” rating on the stock in a research report on Thursday, April 9th. KeyCorp dropped their price target on ResMed from $302.00 to $290.00 and set an “overweight” rating on the stock in a research report on Monday, April 27th. Evercore set a $255.00 price target on ResMed and gave the company an “outperform” rating in a research report on Monday, April 13th. Finally, Robert W. Baird set a $225.00 price target on ResMed in a research report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, ResMed has a consensus rating of “Moderate Buy” and a consensus price target of $286.18.

Read Our Latest Research Report on RMD

ResMed Stock Performance

NYSE:RMD opened at $193.78 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.33 and a current ratio of 3.01. ResMed Inc. has a 52-week low of $180.26 and a 52-week high of $293.81. The firm has a market cap of $28.11 billion, a price-to-earnings ratio of 18.69, a PEG ratio of 1.25 and a beta of 0.80. The business’s fifty day moving average is $211.53 and its 200 day moving average is $236.09.

ResMed (NYSE:RMD – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The medical equipment provider reported $2.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.79 by $0.07. ResMed had a return on equity of 25.35% and a net margin of 27.44%.The company had revenue of $1.43 billion for the quarter, compared to analyst estimates of $1.42 billion. During the same period in the previous year, the company posted $2.37 EPS. The firm’s revenue for the quarter was up 10.8% compared to the same quarter last year. Research analysts predict that ResMed Inc. will post 11.13 EPS for the current year.

ResMed Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 18th. Investors of record on Thursday, May 14th will be paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Thursday, May 14th. ResMed’s payout ratio is presently 23.14%.

Insiders Place Their Bets

In other ResMed news, CEO Michael J. Farrell sold 4,991 shares of the company’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $193.96, for a total value of $968,054.36. Following the transaction, the chief executive officer directly owned 466,256 shares in the company, valued at $90,435,013.76. This represents a 1.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter C. Farrell sold 2,000 shares of the company’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $225.00, for a total value of $450,000.00. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 16,973 shares of company stock worth $3,580,754. 0.65% of the stock is currently owned by corporate insiders.

About ResMed

(Free Report)

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.